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Background: The reversible posterior leukoencephalopathy syndrome is a clinical/radiological syndrome
characterized by headache, seizures, impaired vision, acute hypertension, and typical magnetic resonance imaging
findings. There are several reports in the literature that depict its occurrence in cancer patients. The list of common
anticancer and supportive care drugs that predispose to reversible posterior leukoencephalopathy syndrome is
expanding and includes not only a large number of chemotherapeutic agents but also an increased number of
new targeted drugs, particularly angiogenesis inhibitors such as bevacizumab,sorefenib and sunitinib. Pazopanib is
an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor
receptor, and c-Kit which after a positive phase III randomized clinical trial in patients with advanced renal cell
cancer received FDA approval for the treatment of advanced renal cell carcinoma. Until now no cases of reversible
posterior leukoencephalopathy syndrome induced by pazopanib have been reported.
Case report: We present the case of a 40 years old female patient with heavily pre-treated metastatic renal cell
carcinoma who received pazopanib as salvage treatment. After 21 days of pazopanib therapy the patient referred
to the emergency department with epileptic seizure, impaired vision at both eyes and headache. MRI of the brain
revealed subcortical oedema at the occipital and parietal lobes bilaterally. She was treated with anticonvulsants, i.v.
administration of mannitol and antihypertensives and she recovered completely from her symptoms and was
discharged on the tenth hospital day. A brain MRI performed 3 weeks after showed that the subcortical oedema
had been subsided.
Conclusion: In conclusion this is the first case of pazopanib induced reversible posterior leukoencephalopathy
syndrome. Although usually reversible, this syndrome is a serious and potentially life threatening adverse effect, if
untreated, that should be considered by physicians treating metastatic renal cell carcinoma patients with
pazopanib.
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The reversible posterior leukoencephalopathy syndrome
(RPLS) has been reported as a distinct clinical entity by
several investigators [1,2]. It is a clinical/radiological syn-
drome characterized by headache, seizures, impaired vi-
sion, acute hypertension, and typical magnetic resonance
imaging findings such as hyperintensity on T2-weighted* Correspondence: chelisleonidas@yahoo.gr
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reproduction in any medium, provided the orand fluid-attenuated inversion recovery (FLAIR) images
involving the posterior circulation areas, especially the
parietal and occipital lobes which are usually symmetric.
The hallmark of RPLS is the almost complete recovery
in the majority of the cases of clinical symptoms and
brain imaging findings, which usually occurs within days
to weeks [3].
The correlation of the syndrome with several condi-
tions like hypertensive encephalopathy, eclampsia, colla-
gen vascular disorders, renal dysfunction, thrombotic
thrombocytopenic purpura, acute porphyria, Guillain-his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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agents (especially calcineurin inhibitors like cyclospor-
ine) is well defined [3]. There are numerous case reports
in the literature that depict its occurrence in cancer
patients. The list of common anticancer and supportive
care drugs that predispose to RPLS is expanding and
includes a large number of chemotherapeutic agents
such as cisplatin, cyclophosphamide, high-dose corticos-
teroids, L-asparaginase, and growth supportive factors
such as granulocyte colony-stimulating factor (G-CSF),
and erythropoietin [4]. In the last few years an increased
number of case reports involving new targeted drugs,
particularly angiogenesis inhibitors have been reported.
Agents such as bevacizumab, sunitinib and sorafenib
and other targeted drugs have been implicated in new
cases of RPLS [5-10].
Pazopanib is an oral tyrosine kinase inhibitor (TKI)
targeting vascular endothelial growth factor receptor
(VEGFR), platelet-derived growth factor receptor
(PDGFR), and c-Kit [11]. After a positive phase III ran-
domized clinical trial in patients with advanced renal cell
cancer [12] pazopanib was approved by the US FDA in
October 2009 for the treatment of advanced renal cell
carcinoma (RCC). The toxicity profile of the drug
mimics that of other anti-angiogenesis TKIs consisting
mainly of diarrhoea, hypertension, nausea and fatigue
but until now no cases of RPLS induced by pazopanib
have been reported [13,14].
Case report
We present the case of a 40 years old female patient
who at the age of 30 underwent right nephrectomy for a
clear cell renal cell carcinoma. Five years later she devel-
oped lung and osseous metastases and the biopsy of the
lung lesion revealed metastatic RCC. Bevacizumab plus
interferon-A was administered as 1st line treatment and
the disease evaluation after three months revealed dis-
ease progression. She was treated with sunitinib malate
as 2nd line therapy for one year achieving stable disease
as best response. At relapse, sorafenib was given as 3rd
line treatment and the patient achieved a remarkable
partial response lasting almost for 36 months. Due to
disease progression everolimus was initiated as 4th line
treatment and the disease evaluation after 6 months
revealed progression at her bone metastases, stable dis-
ease at lung lesions and no evidence of brain metastases.
The ECOG performance status of the patient was 1 due
to mild pain at her right hip, she had no history of
hypertension and since pazopanib has shown effective-
ness also in cytokine-pretreated patients with metastatic
RCC [12], we decided to administer pazopanib as 5th line
treatment. Her medical history was insignificant for
other diseases than metastatic renal carcinoma. The
concomitant medication during pazopanib treatmentconsisted of fentanyl transdermal at 25mg and tramadol
hydrochloride.
After 21 days of pazopanib therapy the patient referred
to the emergency department with epileptic seizure,
impaired vision at both eyes and bilateral, temporal and
pulsutive headache. The physical examination revealed
hypertension 165/105 mmHg (grade III toxicity), sus-
pension of both direct and indirect papillary reflexes for
both eyes and bilateral blurred vision and diplopia. On
neurological examination there was no evidence of lat-
eralizing or focal features. Blood tests, including CBC,
blood chemistry, coagulation study and gasometry, were
unremarkable. The performed urine analysis showed no
evidence of significant proteinuria (dipstick staining: 1+)
. Retinoscopy was also insignificant. MRI of the brain
revealed subcortical oedema at the occipital and parietal
lobes bilaterally (hyperintense signals on FLAIR and T2
sequences, absence of lesions on T1 sequence). These
findings are given in Figure. 1: 1.A, 1.B (FLAIR), 1.C, 1.
D (T2), 1.E, 1.F (T1), respectively.
Pazopanib administration was withheld and the patient
was treated with anticonvulsants (phenytoin), i.v. admin-
istration of mannitol and antihypertensives : furosemide
40 mg given i.v on the first date and perindopril 4 mg
given orally the following days. One day later the sei-
zures were stopped, her visual ability was restored and
the blood pressure was normalized after few hours with
furosemide and remained within normal levels the next
days. The headache was more intense the first day but
after the normalization of the blood pressure it was
gradually improved and completely remitted after 5 days.
A lumbar puncture was performed and the cerebrospinal
fluid analysis revealed no cells, normal physical charac-
teristics, normal chemical tests and negative microscopic
examination. In addition the viruses tests for HSV1,
HSV2, CMV, EBV were negative. She completely recov-
ered from her symptoms and was discharged on the
tenth hospital day.
The patient underwent a brain CT scan, two weeks
after the onset of the symptoms, which was negative for
abnormal findings. A brain MRI performed 3 weeks after
confirmed the CT scan findings showing that the sub-
cortical oedema had been subsided from both FLAIR
and T2 sequences. (Figure. 1: 2.A, 2.B, 2.C, 2.D). Due to
the serious nature of the adverse drug reaction re-
administration of pazopanib was not carried out and the
patient was re-challenged with sorafenib because of the
excellent past response. Unfortunately, the patient died
2 months later because of disease progression in the
lungs with no signs of central nervous disease.
Causality assessment carried out using the World
Health Organization-Uppsala Monitoring Centre criteria
revealed that the reaction had ‘probable/likely’ relation-











Figure 1 Brain MRI at the onset of the syndrome (1) and three weeks later (2).: Subcortical oedema at the occipital and parietal lobes
bilaterally shown as hyperintense signals on FLAIR and T2 sequences, absence of lesions on T1 sequence. 1.A, 1.B (FLAIR), 1.C, 1.D (T2), 1.E, 1.F
(T1), respectively. Three weeks later the subcortical oedema had been subsided from both FLAIR and T2 sequences. : 2.A, 2.B, 2.C, 2.D respectively.
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probability of adverse drug reactions and a score of 6
indicated a ‘probable’ relationship [16].
Discussion
The case described above matches both clinical and
radiological criteria of RPLS and to the best of our
knowledge this is the first case of pazopanib induced
RPLS. There are several other neurological complica-
tions such as brain metastasis, stroke or, drug-induced
delirium which can be clinically confused with RPLS,
and therefore, the differential diagnosis of the syndrome
is very important; brain MRI is mandatory for the cor-
rect diagnosis.
The treatment for RPLS is symptomatic, similar to
malignant hypertension, with the goal of lowering dia-
stolic blood pressures to around100 mm Hg within few
hours. Even if hypertension is mild, it is still recom-
mended to reduce blood pressure [4]. Whereas treat-
ment with anticonvulsants is the standard of care for
seizures associated with the acute phase of RPLS, this
does not necessitate longterm antiepileptic treatment
[3]. In cases of RPLS induced by anticancer drugs, it is
recommended that the offending agent be withdrawn, if
possible, and that blood pressure be controlled [4]. Inselected cases where there is no alternative treatment,
anti-VEGF agents can be re-administered at lower dose
with close monitoring of blood pressure [17].
Although the pathogenesis of RPLS is not fully under-
stood there are several mechanisms that could be pro-
posed to explain how the syndrome was triggered by
pazopanib in our patient. The administration of pazopa-
nib for mRCC patients has been frequently correlated
with hypertension ranging between 40-93% and a signifi-
cant proportion of them (9-25%) developed severe
(grade III) hypertension [12,18]. Even a modest increase
in blood pressure, if it is acute, especially in the presence
of an underlying endothelial dysfunction, may exceed
protective autoregulatory mechanisms resulting in
breakdown of the blood–brain-barrier, pathological
vasodilation, capillary leakage which result to extravasa-
tion of fluids into the brain parenchyma [19]. The pos-
terior circulation is more vulnerable to those sudden
changes of blood pressure due to the relative lack of ad-
renergic nerves around pial and intracerebral vessels in
comparison with the anterior circulation of the brain
[20]. Moreover, pazopanib has strong antiangiogenic
properties via inhibition of the VEGF and PDGF path-
ways in vessels cells which suggests that the vascular
endothelium may be an important site of toxicity [11].
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in vascular leak and white matter oedema characteristic
of RPLS especially in the setting of a sudden increase of
the blood pressure like that occurring in our patient.
It is worth mentioning that in a study about the asso-
ciation of RPLS with anticancer drugs [21], a predomin-
ance of RPLS cases affecting women, especially those of
premenopausal age was reported. There are several
genes that are oestrogen-regulated and are actively
involved in the vascular physiology like endothelin-1,
prostacyclin cyclooxygenase, VEGF and endothelial nitric
oxide synthase (eNOS). Our patient was a 40 years old
premenopausal woman and oestrogen activation of those
genes may also contributed to endothelial toxicity and
played a role in the pathogenesis of RPLS [22,23]. This
hypothesis is also fueled by the well established correl-
ation of RPLS and eclampsia.
Conclusion
In conclusion this is the first case of pazopanib induced
RPLS. Although usually reversible, RPLS is a serious and
potentially life threatening adverse effect, if untreated,
that should be considered by physicians treating mRCC
patients with pazopanib. As we have entered the era of
multiple antiangiogenic targeted agents for the treatment
of mRCC more cases of RLPS are anticipated.
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